Amplio Pharma B.V. secures 1.05M EUR investment

The Dutch pharmaceutical start-up Amplio Pharma BV recently signed on to a qualified investment for a total of 1.05M EUR with a consortium of Dutch investors. 

The invested funds are made available to the company directly. However, the Seed Round remains open (until Q4 2025), as the company is looking for further investments within the round of up to 500K EUR.

The raised capital will be used to achieve the first clinical milestone - Proof-of-Principle in Patients with Rheumatoid Arthritis - for the lead candidate drug product NovoBioJect by late 2025.